These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17409804)

  • 61. A phase II study of pirarubicin in malignant pleural mesothelioma.
    Kaukel E; Koschel G; Gatzemeyer U; Salewski E
    Cancer; 1990 Aug; 66(4):651-4. PubMed ID: 2386894
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.
    Maruyama D; Nagai H; Maeda Y; Nakane T; Shimoyama T; Nakazato T; Sakai R; Ishikawa T; Izutsu K; Ueda R; Tobinai K
    Cancer Sci; 2017 Oct; 108(10):2061-2068. PubMed ID: 28771889
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ifosfamide in malignant mesothelioma: a phase II study.
    Andersen MK; Krarup-Hansen A; Mårtensson G; Winther-Nielsen H; Thylen A; Damgaard K; Olling S; Wallin J
    Lung Cancer; 1999 Apr; 24(1):39-43. PubMed ID: 10403693
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma.
    Kadota K; Suzuki K; Colovos C; Sima CS; Rusch VW; Travis WD; Adusumilli PS
    Mod Pathol; 2012 Feb; 25(2):260-71. PubMed ID: 21983936
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study.
    Rosen LE; Karrison T; Ananthanarayanan V; Gallan AJ; Adusumilli PS; Alchami FS; Attanoos R; Brcic L; Butnor KJ; Galateau-Sallé F; Hiroshima K; Kadota K; Klampatsa A; Stang NL; Lindenmann J; Litzky LA; Marchevsky A; Medeiros F; Montero MA; Moore DA; Nabeshima K; Pavlisko EN; Roggli VL; Sauter JL; Sharma A; Sheaff M; Travis WD; Vigneswaran WT; Vrugt B; Walts AE; Tjota MY; Krausz T; Husain AN
    Mod Pathol; 2018 Apr; 31(4):598-606. PubMed ID: 29327706
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma.
    Mulatero CW; Penson RT; Papamichael D; Gower NH; Evans M; Rudd RM
    Lung Cancer; 2001 Jan; 31(1):67-72. PubMed ID: 11162868
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Caelyx in malignant mesothelioma: a phase II EORTC study.
    Baas P; van Meerbeeck J; Groen H; Schouwink H; Burgers S; Daamen S; Giaccone G
    Ann Oncol; 2000 Jun; 11(6):697-700. PubMed ID: 10942058
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
    Goey SH; Eggermont AM; Punt CJ; Slingerland R; Gratama JW; Oosterom R; Oskam R; Bolhuis RL; Stoter G
    Br J Cancer; 1995 Nov; 72(5):1283-8. PubMed ID: 7577483
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
    van Meerbeeck J; Debruyne C; van Zandwijk N; Postmus PE; Pennucci MC; van Breukelen F; Galdermans D; Groen H; Pinson P; van Glabbeke M; van Marck E; Giaccone G
    Br J Cancer; 1996 Sep; 74(6):961-3. PubMed ID: 8826866
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Phase II trial of topotecan for the treatment of mesothelioma.
    Maksymiuk AW; Marschke RF; Tazelaar HD; Grill J; Nair S; Marks RS; Brooks BJ; Mailliard JA; Burton GM; Jett JR
    Am J Clin Oncol; 1998 Dec; 21(6):610-3. PubMed ID: 9856666
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Weekly high-dose cisplatin in malignant pleural mesothelioma.
    Planting AS; Schellens JH; Goey SH; van der Burg ME; de Boer-Dennert M; Stoter G; Verweij J
    Ann Oncol; 1994 Apr; 5(4):373-4. PubMed ID: 8075038
    [TBL] [Abstract][Full Text] [Related]  

  • 72. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.
    Solheim OP; Saeter G; Finnanger AM; Stenwig AE
    Br J Cancer; 1992 Jun; 65(6):956-60. PubMed ID: 1616870
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.
    Yogelzang NJ; Herndon JE; Cirrincione C; Harmon DC; Antman KH; Corson JM; Suzuki Y; Citron ML; Green MR
    Cancer; 1997 Jun; 79(11):2237-42. PubMed ID: 9179072
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis.
    Hong JY; Yoon DH; Yoon SE; Kim SJ; Lee HS; Eom HS; Lee HW; Shin DY; Koh Y; Yoon SS; Jo JC; Kim JS; Kim SJ; Cho SH; Lee WS; Won JH; Kim WS; Suh C
    Sci Rep; 2019 Dec; 9(1):20302. PubMed ID: 31889144
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund.
    Cerbone L; Delfanti S; Crivellari S; De Angelis AM; Mazzeo L; Proto C; Occhipinti M; Lo Russo G; Dellepiane C; Biello F; Alabiso I; Verderame F; Gauna R; De Simone I; Cuppone F; Petraglia S; Pasello G; Ceresoli GL; Garassino MC; Torri V; Grosso F
    Tumori; 2024 Jun; 110(3):168-173. PubMed ID: 38372045
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma.
    Labby ZE; Armato SG; Dignam JJ; Straus C; Kindler HL; Nowak AK
    J Thorac Oncol; 2013 Apr; 8(4):478-86. PubMed ID: 23486268
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group.
    van Breukelen FJ; Mattson K; Giaccone G; van Zandwijk N; Planteydt HT; Kirkpatrick A; Dalesio O
    Eur J Cancer; 1991; 27(12):1627-9. PubMed ID: 1782071
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study.
    Ikeda T; Takemoto S; Senju H; Gyotoku H; Taniguchi H; Shimada M; Dotsu Y; Umeyama Y; Tomono H; Kitazaki T; Fukuda M; Soda H; Yamaguchi H; Fukuda M; Mukae H
    Thorac Cancer; 2020 Jul; 11(7):1972-1978. PubMed ID: 32462731
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical characteristics, treatment and survival outcomes in malignant mesothelioma: eighteen years' experience in Turkey.
    Berk S; Dogan OT; Kilickap S; Epozturk K; Akkurt I; Seyfikli Z
    Asian Pac J Cancer Prev; 2012; 13(11):5735-9. PubMed ID: 23317248
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma.
    O'Reilly EM; Ilson DH; Saltz LB; Heelan R; Martin L; Kelsen DP
    Cancer Invest; 1999; 17(3):195-200. PubMed ID: 10099658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.